Drug Trial Radar · NCT04535193
Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Actual
Start
Nov 5, 2021
Primary completion
Mar 7, 2025
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
- Sponsor type
- Industry
- Collaborators
- Mount Sinai Hospital, New York
- First posted
- Sep 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
Conditions
- Cardiovascular Diseases
Interventions
18F-mFBG for intravenous administrationDrug
Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Chang in 18F-mFBG uptakeTime frame: Up to 210 minutes after dosing
- Evaluation of 18F-mFBG for imaging myocardial sympathetic innervationTime frame: Up to 100 minutes after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mount Sinai Morningside
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.